These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1019 related articles for article (PubMed ID: 27266853)
21. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function. De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961 [TBL] [Abstract][Full Text] [Related]
22. Diuretic response in acute heart failure-an analysis from ASCEND-HF. ter Maaten JM; Dunning AM; Valente MA; Damman K; Ezekowitz JA; Califf RM; Starling RC; van der Meer P; O'Connor CM; Schulte PJ; Testani JM; Hernandez AF; Tang WH; Voors AA Am Heart J; 2015 Aug; 170(2):313-21. PubMed ID: 26299229 [TBL] [Abstract][Full Text] [Related]
23. Hypochloremia and Diuretic Resistance in Heart Failure: Mechanistic Insights. Hanberg JS; Rao V; Ter Maaten JM; Laur O; Brisco MA; Perry Wilson F; Grodin JL; Assefa M; Samuel Broughton J; Planavsky NJ; Ahmad T; Bellumkonda L; Tang WH; Parikh CR; Testani JM Circ Heart Fail; 2016 Aug; 9(8):. PubMed ID: 27507113 [TBL] [Abstract][Full Text] [Related]
24. International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. Mentz RJ; Cotter G; Cleland JG; Stevens SR; Chiswell K; Davison BA; Teerlink JR; Metra M; Voors AA; Grinfeld L; Ruda M; Mareev V; Lotan C; Bloomfield DM; Fiuzat M; Givertz MM; Ponikowski P; Massie BM; O'Connor CM Eur J Heart Fail; 2014 Jun; 16(6):614-24. PubMed ID: 24771609 [TBL] [Abstract][Full Text] [Related]
25. Hemoconcentration-guided diuresis in heart failure. Vaduganathan M; Greene SJ; Fonarow GC; Voors AA; Butler J; Gheorghiade M Am J Med; 2014 Dec; 127(12):1154-9. PubMed ID: 24937157 [TBL] [Abstract][Full Text] [Related]
27. Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial. Ambrosy AP; Khan H; Udelson JE; Mentz RJ; Chioncel O; Greene SJ; Vaduganathan M; Subacuis HP; Konstam MA; Swedberg K; Zannad F; Maggioni AP; Gheorghiade M; Butler J Circ Heart Fail; 2016 May; 9(5):. PubMed ID: 27140204 [TBL] [Abstract][Full Text] [Related]
28. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. Vaduganathan M; Gheorghiade M; Pang PS; Konstam MA; Zannad F; Swedberg K; Grinfeld L; Burnett JC; Krasa HB; Zimmer C; Blair J; Ouyang J; Maggioni AP; J Cardiovasc Med (Hagerstown); 2012 Jul; 13(7):415-22. PubMed ID: 22673023 [TBL] [Abstract][Full Text] [Related]
29. Clinical experience with low-dose continuous infusion of furosemide in acute heart failure: assessment of efficacy and safety. Ng TM; Hshieh S; Chan CY; Elkayam U J Cardiovasc Pharmacol Ther; 2012 Dec; 17(4):373-81. PubMed ID: 22610091 [TBL] [Abstract][Full Text] [Related]
30. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. Ambrosy AP; Vaduganathan M; Mentz RJ; Greene SJ; Subačius H; Konstam MA; Maggioni AP; Swedberg K; Gheorghiade M Am Heart J; 2013 Feb; 165(2):216-25. PubMed ID: 23351825 [TBL] [Abstract][Full Text] [Related]
31. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. O'Connor CM; Miller AB; Blair JE; Konstam MA; Wedge P; Bahit MC; Carson P; Haass M; Hauptman PJ; Metra M; Oren RM; Patten R; Piña I; Roth S; Sackner-Bernstein JD; Traver B; Cook T; Gheorghiade M; Am Heart J; 2010 May; 159(5):841-849.e1. PubMed ID: 20435194 [TBL] [Abstract][Full Text] [Related]
32. Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality. Davison BA; Metra M; Senger S; Edwards C; Milo O; Bloomfield DM; Cleland JG; Dittrich HC; Givertz MM; O'Connor CM; Massie BM; Ponikowski P; Teerlink JR; Voors AA; Cotter G Eur J Heart Fail; 2016 Aug; 18(8):1041-50. PubMed ID: 27114058 [TBL] [Abstract][Full Text] [Related]
33. The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. Givertz MM; Massie BM; Fields TK; Pearson LL; Dittrich HC; J Am Coll Cardiol; 2007 Oct; 50(16):1551-60. PubMed ID: 17936154 [TBL] [Abstract][Full Text] [Related]
34. Racial Differences in Diuretic Efficiency, Plasma Renin, and Rehospitalization in Subjects With Acute Heart Failure. Morris AA; Nayak A; Ko YA; D'Souza M; Felker GM; Redfield MM; Tang WHW; Testani JM; Butler J Circ Heart Fail; 2020 Jul; 13(7):e006827. PubMed ID: 32635768 [TBL] [Abstract][Full Text] [Related]
35. A combined clinical and biomarker approach to predict diuretic response in acute heart failure. ter Maaten JM; Valente MA; Metra M; Bruno N; O'Connor CM; Ponikowski P; Teerlink JR; Cotter G; Davison B; Cleland JG; Givertz MM; Bloomfield DM; Dittrich HC; van Veldhuisen DJ; Hillege HL; Damman K; Voors AA Clin Res Cardiol; 2016 Feb; 105(2):145-53. PubMed ID: 26280875 [TBL] [Abstract][Full Text] [Related]
36. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure. Katsumata M; Hirawa N; Sumida K; Kagimoto M; Ehara Y; Okuyama Y; Fujita M; Fujiwara A; Kobayashi M; Kobayashi Y; Yamamoto Y; Saka S; Yatsu K; Fujikawa T; Toya Y; Yasuda G; Tamura K; Umemura S Clin Exp Nephrol; 2017 Oct; 21(5):858-865. PubMed ID: 28190113 [TBL] [Abstract][Full Text] [Related]
37. Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: an analysis from diuretic optimization strategies in acute heart failure. Shah RV; McNulty S; O'Connor CM; Felker GM; Braunwald E; Givertz MM Am Heart J; 2012 Dec; 164(6):862-8. PubMed ID: 23194486 [TBL] [Abstract][Full Text] [Related]
38. Medical therapy for acute decompensated heart failure: what recent clinical trials have taught us about diuretics and vasodilators. Marti C; Cole R; Kalogeropoulos A; Georgiopoulou V; Butler J Curr Heart Fail Rep; 2012 Mar; 9(1):1-7. PubMed ID: 21874282 [TBL] [Abstract][Full Text] [Related]
39. Early diuretic strategies and the association with In-hospital and Post-discharge outcomes in acute heart failure. Fudim M; Spates T; Sun JL; Kittipibul V; Testani JM; Starling RC; Tang WHW; Hernandez AF; Felker GM; O'Connor CM; Mentz RJ Am Heart J; 2021 Sep; 239():110-119. PubMed ID: 34052212 [TBL] [Abstract][Full Text] [Related]
40. Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome--an analysis from RELAX-AHF. Voors AA; Davison BA; Teerlink JR; Felker GM; Cotter G; Filippatos G; Greenberg BH; Pang PS; Levin B; Hua TA; Severin T; Ponikowski P; Metra M; Eur J Heart Fail; 2014 Nov; 16(11):1230-40. PubMed ID: 25287144 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]